February 2, 2021 -- Adverum Biotechnologies has published preclinical data on its intravitreal gene therapy candidate ADVM-022 in Translational Vision Science & Technology.
ADVM-022 uses a propriety vector capsid, AAV.7m8, carrying an aflibercept (vascular endothelial growth factor [VEGF] inhibitor) coding sequence under the control of a proprietary expression cassette.
The nonhuman primate data presented in the study represents the longest safety and expression study of the candidate to date, with measurements extended 30 months post-single intravitreal injection. From the study, ADVM-022 appears to be safe and well-tolerated with sustained therapeutic levels of aflibercept expression post intravitreal injection of the product.
ADVM-022 is currently in clinical trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company plans to begin a pivotal trial in mid-2021 for ADVM-022 in wet AMD.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
